Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression.
Eleanor J Cole, Katy H Stimpson, Brandon S Bentzley...
https://pubmed.ncbi.nlm.nih.gov/32252538/Actively Recruiting
Led by Mayo Clinic · Updated on 2026-11-03
60
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying whether an experimental brain stimulation treatment called intermittent theta burst stimulation iTBS, a type of transcranial magnetic stimulation TMS, can be improved using brain wave recordings from electroencephalography EEG for adults with Major Depressive Disorder MDD. This pilot study tests a closed-loop method where the timing of TMS pulses is guided by specific phases of brain waves. The study aims to evaluate whether this approach is feasible for improving treatment outcomes. Participants will receive one of three types of EEG-guided iTBS, all involving stimulation to the left dorsolateral prefrontal cortex DLPFC using FDA-cleared TMS devices. The three groups differ by when the TMS pulses are delivered in relation to the participants brain wave at the peak of theta waves, at the trough, or at a random phase control. Treatments are given once daily, five days a week, for six weeks, with a total of 30 sessions. EEG caps and neuronavigation guided by MRI or a standard brain atlas will be used to ensure accurate treatment delivery. During the study, participants will be monitored weekly for six weeks through visits where depression severity is assessed using standard scales, including the Hamilton Depression Rating Scale, Montgomery-Asberg Depression Rating Scale, and others. Follow-up visits occur monthly for three months and can be in person or remote. Participants will continue their usual psychotherapy and medications with stable doses. The main measure is the feasibility of the EEG-guided iTBS at six and twelve weeks after treatment, alongside changes in depression symptoms assessed throughout the study.
CONDITIONS
EEG-Guided Transcranial Magnetic Stimulation for Adults With Depression
C
Courtney Caves
S
Sarah Purdy
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mayo Clinic
Lead Sponsor
University of Minnesota
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Closed‑loop iTBS (peak phase) | Closed‑loop iTBS (trough phase) | Random‑phase iTBS (active comparator) | Standard FDA‑cleared TMS |
|---|---|---|---|---|
| What it is | iTBS directed to peak of individual theta rhythm detected via EEG | iTBS directed to trough of individual theta rhythm detected via EEG | iTBS delivered at random phase relative to EEG theta rhythm | FDA‑cleared repetitive TMS protocols including iTBS now used in TRD |
| Role in trial | Investigational experimental arm | Investigational experimental arm | Active comparator arm within trial | Clinical standard care comparator (external context only) |
| Primary use | To assess feasibility and potential advantage of EEG‑peak‑locked iTBS in TRD | To assess feasibility and potential advantage of EEG‑trough‑locked iTBS in TRD | Comparison control for closed‑loop iTBS feasibility | Established TMS protocols for treatment‑resistant depression |
| How it is given or performed | iTBS bursts aligned to individual theta‑rhythm peak via EEG, delivered daily for 5 days/week over 6 weeks | iTBS bursts aligned to individual theta‑rhythm trough via EEG, delivered daily for 5 days/week over 6 weeks | iTBS delivered at random EEG phase, daily for 5 days/week over 6 weeks | Daily iTBS over 4‑6 weeks as FDA‑cleared standard protocol for TRD |
| Evidence status | Feasibility under investigation; no published clinical efficacy data yet | Feasibility under investigation; no published clinical efficacy data yet | Investigational active comparator; efficacy not yet established in published literature | Established as effective for treatment‑resistant depression in adults based on FDA‑cleared TMS protocols |
| Important risks | Risks similar to standard TMS (e.g., rare seizure risk, scalp discomfort); safety under closed‑loop approach not yet established | Risks similar to standard TMS (e.g., rare seizure risk, scalp discomfort); safety under closed‑loop approach not yet established | Risks comparable to standard iTBS (e.g., rare seizure, headache), under investigation | TMS is non‑invasive with favorable safety profile; uncommon side effects include temporary headache or discomfort |
| Important limitations | Feasibility study with no efficacy data yet; small sample and experimental EEG alignment may increase complexity | Same feasibility limitations and technical complexity as peak‑phase arm | As active comparator, does not reflect standard care; efficacy unknown pending trial results | Not part of trial; provides context but not directly compared in study; protocols vary across centers |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Visits at screening and baseline assessments
Duration - 6 weeks
Participants receive one of three types of EEG-guided intermittent theta burst stimulation (iTBS) to the left dorsolateral prefrontal cortex, with stimulation timed to different phases of brain waves. Treatments are given once daily, five days a week, for six weeks.
Daily sessions five days per week; weekly clinical assessments
Duration - 3 months
Participants are monitored monthly for three months after treatment to assess longer-term effects and symptom changes. Follow-up visits can be in person or remote based on participant preference.
Monthly visits (in person or remote)
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Eleanor J Cole, Katy H Stimpson, Brandon S Bentzley...
https://pubmed.ncbi.nlm.nih.gov/32252538/Anne Weigand, Andreas Horn, Ruth Caballero...
https://pubmed.ncbi.nlm.nih.gov/29274805/Tyler S Kaster, Jonathan Downar, Fidel Vila-Rodriguez...
https://pubmed.ncbi.nlm.nih.gov/30764649/Daniel M Blumberger, Fidel Vila-Rodriguez, Kevin E Thorpe...
https://pubmed.ncbi.nlm.nih.gov/29726344/Sina Shirinpour, Ivan Alekseichuk, Kathleen Mantell...
https://pubmed.ncbi.nlm.nih.gov/32554882/Mayo Clinic
Lead Sponsor
University of Minnesota
Collaborating Sponsor